Dr. Bajorin on Chemotherapy Approaches in Bladder Cancer

Video

In Partnership With:

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Historically, bladder cancer has been treated with chemotherapy in metastatic and muscle-invasive disease, Bajorin says. In the metastatic setting, there are 2 standard chemotherapy regimens. For patients who are fit, in good physical condition, and have good renal function, cisplatin-based therapy is the standard approach. One regimen is MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) and the other is a combination of gemcitabine and cisplatin. Both treatments are considered interchangeable with regard to first-line therapy, he adds.

However, in a frailer and older patient population, kidney function can be compromised. Therefore, cisplatin is not possible in many of those patients, he explains. Because of this, carboplatin-based therapy has been the mainstay treatment. There have been randomized trials of carboplatin plus gemcitabine showing it as the best tolerated therapy and, in some patients, it can have a substantial benefit.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD